Pathogenesis in Menstrual Cycle-Linked CNS Disorders
: That 3alpha‐hydroxy‐5alpha/beta‐pregnane steroids (GABA steroids) have modulatory effects on the GABA‐A receptor is well known. In behavioral studies in animals high exogenous dosages give concentrations not usually reached in the brain under physiological conditions. Animal and human studies show...
Saved in:
Published in: | Annals of the New York Academy of Sciences Vol. 1007; no. 1; pp. 42 - 53 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Oxford, UK
Blackwell Publishing Ltd
01-12-2003
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | : That 3alpha‐hydroxy‐5alpha/beta‐pregnane steroids (GABA steroids) have modulatory effects on the GABA‐A receptor is well known. In behavioral studies in animals high exogenous dosages give concentrations not usually reached in the brain under physiological conditions. Animal and human studies show that GABA‐A receptor‐positive modulators like barbiturates, benzodiazepines, alcohol, and allopregnanolone have a bimodal effect. In pharmacological concentrations they are CNS depressants, anesthetic, antiepileptic, and anxiolytic. In low dosages and concentrations, reached endogenously, they can induce adverse emotional reactions in up to 20% of individuals. GABA steroids can also induce tolerance to themselves and similar substances, and rebound occurs at withdrawal. Menstrual cycle‐linked disorders can be understood by the concept that they are caused by the action of endogenously produced GABA‐steroids through three mechanisms: (a) direct action, (b) tolerance induction, and (c) withdrawal effect. Examples of symptoms and disorders caused by the direct action of GABA steroids are sedation, memory and learning disturbance, clumsiness, increased appetite, worsening of petit mal epilepsy, negative mood as tension, irritability and depression during hormone treatments, and the premenstrual dysphoric disorder (PMDD). A continuous exposure to GABA steroids causes tolerance, and women with PMDD are less sensitive to GABA‐A modulators. A malfunctioning GABA‐A receptor system is related to stress sensitivity, concentration difficulties, loss of impulse control, irritability, anxiety, and depression. An example of withdrawal effect is “catamenial epilepsy,” when seizures increase during menstruation after the withdrawal of GABA steroids. Similar phenomena occur at stress since the adrenals produce GABA steroids during stress. |
---|---|
AbstractList | That 3alpha-hydroxy-5alpha/beta-pregnane steroids (GABA steroids) have modulatory effects on the GABA-A receptor is well known. In behavioral studies in animals high exogenous dosages give concentrations not usually reached in the brain under physiological conditions. Animal and human studies show that GABA-A receptor-positive modulators like barbiturates, benzodiazepines, alcohol, and allopregnanolone have a bimodal effect. In pharmacological concentrations they are CNS depressants, anesthetic, antiepileptic, and anxiolytic. In low dosages and concentrations, reached endogenously, they can induce adverse emotional reactions in up to 20% of individuals. GABA steroids can also induce tolerance to themselves and similar substances, and rebound occurs at withdrawal. Menstrual cycle-linked disorders can be understood by the concept that they are caused by the action of endogenously produced GABA-steroids through three mechanisms: (a) direct action, (b) tolerance induction, and (c) withdrawal effect. Examples of symptoms and disorders caused by the direct action of GABA steroids are sedation, memory and learning disturbance, clumsiness, increased appetite, worsening of petit mal epilepsy, negative mood as tension, irritability and depression during hormone treatments, and the premenstrual dysphoric disorder (PMDD). A continuous exposure to GABA steroids causes tolerance, and women with PMDD are less sensitive to GABA-A modulators. A malfunctioning GABA-A receptor system is related to stress sensitivity, concentration difficulties, loss of impulse control, irritability, anxiety, and depression. An example of withdrawal effect is "catamenial epilepsy," when seizures increase during menstruation after the withdrawal of GABA steroids. Similar phenomena occur at stress since the adrenals produce GABA steroids during stress. A bstract : That 3alpha‐hydroxy‐5alpha/beta‐pregnane steroids (GABA steroids) have modulatory effects on the GABA‐A receptor is well known. In behavioral studies in animals high exogenous dosages give concentrations not usually reached in the brain under physiological conditions. Animal and human studies show that GABA‐A receptor‐positive modulators like barbiturates, benzodiazepines, alcohol, and allopregnanolone have a bimodal effect. In pharmacological concentrations they are CNS depressants, anesthetic, antiepileptic, and anxiolytic. In low dosages and concentrations, reached endogenously, they can induce adverse emotional reactions in up to 20% of individuals. GABA steroids can also induce tolerance to themselves and similar substances, and rebound occurs at withdrawal. Menstrual cycle‐linked disorders can be understood by the concept that they are caused by the action of endogenously produced GABA‐steroids through three mechanisms: (a) direct action, (b) tolerance induction, and (c) withdrawal effect. Examples of symptoms and disorders caused by the direct action of GABA steroids are sedation, memory and learning disturbance, clumsiness, increased appetite, worsening of petit mal epilepsy, negative mood as tension, irritability and depression during hormone treatments, and the premenstrual dysphoric disorder (PMDD). A continuous exposure to GABA steroids causes tolerance, and women with PMDD are less sensitive to GABA‐A modulators. A malfunctioning GABA‐A receptor system is related to stress sensitivity, concentration difficulties, loss of impulse control, irritability, anxiety, and depression. An example of withdrawal effect is “catamenial epilepsy,” when seizures increase during menstruation after the withdrawal of GABA steroids. Similar phenomena occur at stress since the adrenals produce GABA steroids during stress. : That 3alpha‐hydroxy‐5alpha/beta‐pregnane steroids (GABA steroids) have modulatory effects on the GABA‐A receptor is well known. In behavioral studies in animals high exogenous dosages give concentrations not usually reached in the brain under physiological conditions. Animal and human studies show that GABA‐A receptor‐positive modulators like barbiturates, benzodiazepines, alcohol, and allopregnanolone have a bimodal effect. In pharmacological concentrations they are CNS depressants, anesthetic, antiepileptic, and anxiolytic. In low dosages and concentrations, reached endogenously, they can induce adverse emotional reactions in up to 20% of individuals. GABA steroids can also induce tolerance to themselves and similar substances, and rebound occurs at withdrawal. Menstrual cycle‐linked disorders can be understood by the concept that they are caused by the action of endogenously produced GABA‐steroids through three mechanisms: (a) direct action, (b) tolerance induction, and (c) withdrawal effect. Examples of symptoms and disorders caused by the direct action of GABA steroids are sedation, memory and learning disturbance, clumsiness, increased appetite, worsening of petit mal epilepsy, negative mood as tension, irritability and depression during hormone treatments, and the premenstrual dysphoric disorder (PMDD). A continuous exposure to GABA steroids causes tolerance, and women with PMDD are less sensitive to GABA‐A modulators. A malfunctioning GABA‐A receptor system is related to stress sensitivity, concentration difficulties, loss of impulse control, irritability, anxiety, and depression. An example of withdrawal effect is “catamenial epilepsy,” when seizures increase during menstruation after the withdrawal of GABA steroids. Similar phenomena occur at stress since the adrenals produce GABA steroids during stress. |
Author | STRÖMBERG, JESSICA ANDREÉ, LOTTA WAHLSTRÖM, GÖRAN NYBERG, SIGRID JOHANSSON, INGA-MAJ LUNDGREN, PER ISAKSSON, MONICA BÄCKSTRÖM, TORBJÖRN SUNDSTRÖM-POROMAA, INGER ZHU, DI ANDERSSON, AGNETA ZINGMARK, ELISABETH TURKMEN, SAHRUH ÖDMARK, INGA-STINA WANG, MINGDE HAAGE, DAVID WIHLBÄCK, ANNA-CARIN BIRZNIECE, VITA BIXO, MARIE BJÖRN, INGER LINDBLAD, CHARLOTT |
Author_xml | – sequence: 1 givenname: TORBJÖRN surname: BÄCKSTRÖM fullname: BÄCKSTRÖM, TORBJÖRN email: Torbjorn.Backstrom@Obgyn.umu.se organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden – sequence: 2 givenname: AGNETA surname: ANDERSSON fullname: ANDERSSON, AGNETA organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden – sequence: 3 givenname: LOTTA surname: ANDREÉ fullname: ANDREÉ, LOTTA organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden – sequence: 4 givenname: VITA surname: BIRZNIECE fullname: BIRZNIECE, VITA organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden – sequence: 5 givenname: MARIE surname: BIXO fullname: BIXO, MARIE organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden – sequence: 6 givenname: INGER surname: BJÖRN fullname: BJÖRN, INGER organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden – sequence: 7 givenname: DAVID surname: HAAGE fullname: HAAGE, DAVID organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden – sequence: 8 givenname: MONICA surname: ISAKSSON fullname: ISAKSSON, MONICA organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden – sequence: 9 givenname: INGA-MAJ surname: JOHANSSON fullname: JOHANSSON, INGA-MAJ organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden – sequence: 10 givenname: CHARLOTT surname: LINDBLAD fullname: LINDBLAD, CHARLOTT organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden – sequence: 11 givenname: PER surname: LUNDGREN fullname: LUNDGREN, PER organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden – sequence: 12 givenname: SIGRID surname: NYBERG fullname: NYBERG, SIGRID organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden – sequence: 13 givenname: INGA-STINA surname: ÖDMARK fullname: ÖDMARK, INGA-STINA organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden – sequence: 14 givenname: JESSICA surname: STRÖMBERG fullname: STRÖMBERG, JESSICA organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden – sequence: 15 givenname: INGER surname: SUNDSTRÖM-POROMAA fullname: SUNDSTRÖM-POROMAA, INGER organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden – sequence: 16 givenname: SAHRUH surname: TURKMEN fullname: TURKMEN, SAHRUH organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden – sequence: 17 givenname: GÖRAN surname: WAHLSTRÖM fullname: WAHLSTRÖM, GÖRAN organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden – sequence: 18 givenname: MINGDE surname: WANG fullname: WANG, MINGDE organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden – sequence: 19 givenname: ANNA-CARIN surname: WIHLBÄCK fullname: WIHLBÄCK, ANNA-CARIN organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden – sequence: 20 givenname: DI surname: ZHU fullname: ZHU, DI organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden – sequence: 21 givenname: ELISABETH surname: ZINGMARK fullname: ZINGMARK, ELISABETH organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/14993039$$D View this record in MEDLINE/PubMed https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-16450$$DView record from Swedish Publication Index |
BookMark | eNqFkM1P2zAYhy3EBKXjvBvKidNS_BW7PlaFdaCum9RtsNMrJ3kDhtTp7EbQ_55UqeDIyZfn97zyc0IOfeORkC-Mjhgz6sJ6b-s4YnysRpRmB2TAtDSpUoIfkgGlWqdjw8UxOYnxkdKOk_qIHDNpjKDCDIj8ZTcPzT16jC4mzic_0MdNaG2dTLdFjenc-Scsk-limVy62IQSQ_xMPlXdWTzdv0Py59vV7-n3dP5zdj2dzNMi44ynVuoi51luRY4iLyRWeWm55llZMVZIQZVVRpZccCtZUeaSlxalqqpqnDFLuRiSr703PuO6zWEd3MqGLTTWwaX7O4Em3EO7aoEpmdEOP-_xdWj-txg3sHKxwLq2Hps2gmaZMKxrMyQXPViEJsaA1ZuZUdh1hb4r7LpC17VbnO3Vbb7C8p3fh-wA0QPPrsbtRz5Y_Jss5e6Dab9ycYMvbysbnkBpoTO4XcxgeauluLkzMBOvBp-WCw |
CitedBy_id | crossref_primary_10_1007_s10072_011_0532_5 crossref_primary_10_1007_s00213_005_0168_3 crossref_primary_10_1002_hbm_24069 crossref_primary_10_1016_j_physbeh_2008_08_015 crossref_primary_10_3389_fphar_2021_706894 crossref_primary_10_1080_10673220902891836 crossref_primary_10_1016_j_pneurobio_2013_09_003 crossref_primary_10_1007_s10989_014_9418_8 crossref_primary_10_1016_j_yhbeh_2019_104655 crossref_primary_10_1111_j_1365_2265_2007_02744_x crossref_primary_10_1007_s11064_009_9947_2 crossref_primary_10_1016_j_jad_2014_12_040 crossref_primary_10_3389_fmed_2017_00144 crossref_primary_10_1124_jpet_113_203653 crossref_primary_10_1016_j_tem_2008_07_004 crossref_primary_10_1016_j_ajog_2009_03_016 crossref_primary_10_1210_jc_2005_2785 crossref_primary_10_1016_j_jsbmb_2010_06_003 crossref_primary_10_1371_journal_pone_0119351 crossref_primary_10_1016_j_pharmthera_2007_03_011 crossref_primary_10_1016_j_brainres_2014_11_051 crossref_primary_10_1016_j_yebeh_2008_02_004 crossref_primary_10_1007_s00404_009_1347_y crossref_primary_10_1371_journal_pone_0030608 crossref_primary_10_1016_j_pbb_2006_06_007 crossref_primary_10_1186_1744_8069_5_2 crossref_primary_10_2217_17455057_3_4_395 crossref_primary_10_4155_fmc_10_178 crossref_primary_10_2174_2211556008666190724113554 crossref_primary_10_1016_j_steroids_2011_07_002 crossref_primary_10_1016_j_yfrne_2020_100873 crossref_primary_10_1007_s00429_016_1197_x crossref_primary_10_1038_mp_2010_120 crossref_primary_10_1016_j_neuron_2008_06_019 crossref_primary_10_1016_j_pharmthera_2007_03_007 crossref_primary_10_1007_s00737_013_0327_1 crossref_primary_10_1016_j_rbre_2014_12_010 crossref_primary_10_1155_2017_8459287 crossref_primary_10_1111_j_1440_1681_2008_04946_x crossref_primary_10_1002_brb3_890 crossref_primary_10_1016_j_yfrne_2012_08_005 crossref_primary_10_1002_brb3_1845 crossref_primary_10_1002_jnr_24205 crossref_primary_10_1016_j_psyneuen_2010_08_006 crossref_primary_10_1016_j_brainresrev_2007_05_012 crossref_primary_10_1016_j_nlm_2018_08_016 crossref_primary_10_3390_biom12070868 crossref_primary_10_1016_j_jad_2018_12_133 crossref_primary_10_1007_s11845_020_02275_7 crossref_primary_10_1111_j_1468_2982_2006_01061_x crossref_primary_10_1517_14656566_8_7_989 crossref_primary_10_3389_fncel_2014_00222 crossref_primary_10_1016_j_psyneuen_2009_07_005 crossref_primary_10_1038_nature05324 crossref_primary_10_1080_09513590701253511 crossref_primary_10_1016_j_jad_2012_02_010 crossref_primary_10_1111_j_1476_5381_2010_01059_x crossref_primary_10_1111_j_1399_5618_2011_00921_x crossref_primary_10_1007_s00213_008_1372_8 crossref_primary_10_1016_j_brainres_2007_06_057 crossref_primary_10_1016_j_pscychresns_2014_10_020 crossref_primary_10_1111_bph_12861 crossref_primary_10_1016_j_neuroscience_2005_10_016 crossref_primary_10_1007_s00213_014_3567_5 crossref_primary_10_1016_j_pharmthera_2005_05_009 crossref_primary_10_1016_j_pharmthera_2007_04_011 crossref_primary_10_1016_j_yfrne_2023_101098 crossref_primary_10_1155_2016_7950781 crossref_primary_10_1016_j_jad_2012_06_038 crossref_primary_10_3389_fphar_2016_00403 crossref_primary_10_1097_01_ALC_0000171486_97638_BC crossref_primary_10_1007_s11920_015_0627_4 crossref_primary_10_1038_nn1469 crossref_primary_10_1016_j_contraception_2012_09_024 crossref_primary_10_1016_j_jbtep_2016_07_002 crossref_primary_10_1111_j_1440_1681_2010_05352_x crossref_primary_10_1016_j_srhc_2011_07_001 crossref_primary_10_1080_09513590400018223 crossref_primary_10_1097_00012272_200510000_00008 crossref_primary_10_1016_j_neuropharm_2014_09_021 crossref_primary_10_1111_j_1467_789X_2005_00188_x crossref_primary_10_1159_000530805 crossref_primary_10_1586_erp_09_14 crossref_primary_10_1038_s41598_019_51498_x crossref_primary_10_1177_2631831818824439 crossref_primary_10_1007_s10608_016_9788_7 crossref_primary_10_1111_jne_12063 crossref_primary_10_1517_14656566_9_3_429 crossref_primary_10_1016_j_brainresrev_2005_11_001 crossref_primary_10_1038_sj_mp_4002030 crossref_primary_10_1016_j_jpag_2006_09_014 crossref_primary_10_1007_s13105_011_0127_x crossref_primary_10_1016_j_maturitas_2008_10_008 crossref_primary_10_1111_apha_12122 crossref_primary_10_1515_HMBCI_2010_070 crossref_primary_10_4236_psych_2019_107068 crossref_primary_10_1016_j_jad_2013_06_042 crossref_primary_10_1016_j_biopsych_2010_09_029 crossref_primary_10_1007_s12529_016_9564_9 crossref_primary_10_1016_j_rbr_2014_12_009 crossref_primary_10_1016_j_ajog_2009_07_061 |
Cites_doi | 10.1523/JNEUROSCI.20-08-02758.2000 10.1016/0169-328X(96)00087-3 10.1016/S0306-4530(01)00010-5 10.1007/BF02247439 10.2165/00023210-200317050-00003 10.1530/acta.0.1250132 10.1016/1059-1311(92)90012-P 10.1212/WNL.54.8.1691 10.1056/NEJM199801223380401 10.1210/jc.85.10.3840 10.1111/j.1530-0277.1990.tb00462.x 10.1007/0-306-47141-8_9 10.1016/S0140-6736(56)90003-4 10.1523/JNEUROSCI.17-05-01848.1997 10.1300/J094v06n04_02 10.3109/00016348809004191 10.1210/jc.81.3.1076 10.1159/000054307 10.1016/S0014-2999(98)00629-3 10.1073/pnas.95.18.10734 10.1111/j.1600-0773.1987.tb01770.x 10.1080/713602990 10.1097/00004714-200210000-00013 10.1016/0006-8993(90)91792-F 10.1016/S0304-3940(98)00479-0 10.1046/j.1471-4159.2000.0751390.x 10.1016/0165-6147(91)90531-V 10.1016/S0010-9452(13)80139-6 10.1016/0006-8993(84)90299-3 10.1016/S0006-8993(02)02414-9 10.1126/science.2422758 10.1016/S0091-3057(96)00218-3 10.1016/0039-128X(90)90031-6 10.1111/j.1360-0443.1994.tb03743.x 10.1016/S0074-7742(01)46071-5 10.1210/jc.83.6.1988 10.1016/S0006-8993(01)02565-3 10.15288/jsas.1993.s11.170 10.1111/j.1530-0277.1994.tb00928.x 10.1111/j.1600-0404.1976.tb04363.x 10.1111/j.1528-1157.1997.tb01197.x 10.1016/S0091-3057(96)00132-3 10.1016/0306-4530(90)90072-H 10.1111/j.1365-2044.1990.tb14683.x 10.1007/s002130000587 10.1530/eje.0.1480571 10.3109/00016348509155154 10.1016/S0893-133X(97)00086-9 10.1210/endo-70-2-196 10.1067/mje.2002.124572 10.1016/0165-0327(94)90059-0 10.1016/S0306-4530(97)00064-4 10.1073/pnas.95.22.13284 10.1210/jc.2002-020755 10.1007/s002280050606 10.3109/01674828309081250 10.1073/pnas.88.10.4553 10.1016/S0306-4530(96)00035-2 10.1016/S0006-8993(98)00782-3 10.1056/NEJM198411223112104 10.1096/fasebj.6.6.1347506 10.1210/jcem-68-1-125 10.1212/WNL.9.5.352 10.1034/j.1600-0412.2000.079005405.x 10.1111/j.1748-1716.1987.tb08202.x 10.1016/0960-0760(95)00179-4 10.1016/0006-8993(91)90761-J 10.1016/0006-8993(88)90615-4 10.1046/j.1468-2982.1996.1601011.x 10.1212/WNL.38.8.1233 10.1034/j.1600-0412.1999.781011.x 10.1067/mob.2000.107781 10.1038/31948 10.1016/S0006-8993(97)00455-1 10.1016/0091-3057(95)02142-6 10.1016/S0091-3057(00)00299-9 10.1038/npp.1993.70 10.1016/0022-3999(87)90097-3 |
ContentType | Journal Article |
DBID | BSCLL CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 ADTPV AOWAS D93 |
DOI | 10.1196/annals.1286.005 |
DatabaseName | Istex Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic SwePub SwePub Articles SWEPUB Umeå universitet |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE CrossRef MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Sciences (General) Biology |
EISSN | 1749-6632 |
EndPage | 53 |
ExternalDocumentID | oai_DiVA_org_umu_16450 10_1196_annals_1286_005 14993039 NYAS42 ark_67375_WNG_SW743JX9_G |
Genre | article Research Support, Non-U.S. Gov't Journal Article Review |
GroupedDBID | --- --Z -~X .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1CY 1OB 1OC 23M 31~ 33P 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52S 52T 52U 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 692 6J9 702 79B 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A03 AAESR AAEVG AAHHS AAMDK AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABLJU ABPVW ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACIWK ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADEOM ADIZJ ADKYN ADMGS ADOJD ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AELAQ AENEX AEQDE AEUQT AEUYR AFBPY AFFNX AFFPM AFGKR AFPWT AFRAH AFSWV AFZJQ AHBTC AHEFC AHMBA AI. AIAGR AITYG AIURR AIWBW AJBDE AJXKR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ATUGU AUFTA AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BIYOS BMNLL BMXJE BNHUX BROTX BRXPI BSCLL BY8 C45 CAG CO8 COF CS3 D-E D-F DC6 DCZOG DPXWK DR2 DRFUL DRSTM EBD EBS EJD EMOBN ESX F00 F01 F04 F5P FEDTE FZ0 G-S G.N GODZA H.T H.X HF~ HGLYW HVGLF HZI HZ~ I-F IH2 IX1 J0M K48 L7B LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRSTM MSFUL MSSTM MXFUL MXSTM N04 N05 N9A NF~ NHB O66 O9- OHT OIG OK1 OVD P2P P2W P2X P4D PALCI PQQKQ Q.N Q11 QB0 R.K RAG RIWAO RJQFR ROL RX1 S10 SAMSI SJN SUPJJ SV3 TEORI TUS UB1 UPT V8K VH1 W8V W99 WBKPD WH7 WHWMO WIH WIK WOHZO WQJ WRC WUP WVDHM WXSBR X7M XG1 YBU YOC YSK ZGI ZKB ZXP ZZTAW ~02 ~IA ~KM ~WT CGR CUY CVF ECM EIF NPM AAMNL AAYXX CITATION 7X8 ADTPV AOWAS D93 |
ID | FETCH-LOGICAL-c5212-a47cb25ba3be3bc4efbda2725df11c4306a694d232a41cdb42dae46fff851a023 |
IEDL.DBID | 33P |
ISSN | 0077-8923 1749-6632 |
IngestDate | Sat Aug 24 00:09:47 EDT 2024 Fri Aug 16 12:02:40 EDT 2024 Fri Nov 22 00:07:56 EST 2024 Sat Sep 28 08:35:49 EDT 2024 Sat Aug 24 00:58:51 EDT 2024 Wed Oct 30 09:47:51 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Receptors GABA-A/physiology |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c5212-a47cb25ba3be3bc4efbda2725df11c4306a694d232a41cdb42dae46fff851a023 |
Notes | istex:AE1A31F3866913A7C81AA531D640CEB1E72A3013 ark:/67375/WNG-SW743JX9-G ArticleID:NYAS42 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1196/annals.1286.005 |
PMID | 14993039 |
PQID | 71539166 |
PQPubID | 23479 |
PageCount | 12 |
ParticipantIDs | swepub_primary_oai_DiVA_org_umu_16450 proquest_miscellaneous_71539166 crossref_primary_10_1196_annals_1286_005 pubmed_primary_14993039 wiley_primary_10_1196_annals_1286_005_NYAS42 istex_primary_ark_67375_WNG_SW743JX9_G |
PublicationCentury | 2000 |
PublicationDate | December 2003 |
PublicationDateYYYYMMDD | 2003-12-01 |
PublicationDate_xml | – month: 12 year: 2003 text: December 2003 |
PublicationDecade | 2000 |
PublicationPlace | Oxford, UK |
PublicationPlace_xml | – name: Oxford, UK – name: United States |
PublicationTitle | Annals of the New York Academy of Sciences |
PublicationTitleAlternate | Ann N Y Acad Sci |
PublicationYear | 2003 |
Publisher | Blackwell Publishing Ltd |
Publisher_xml | – name: Blackwell Publishing Ltd |
References | Petursson, H. 1994. The benzodiazepine withdrawal syndrome. Addiction 89: 1455-1459. Norberg, L. et al. 1987. The anaesthetic potency of 3 alpha-hydroxy-5 alpha-pregnan-20-one and 3 alpha-hydroxy-5 beta-pregnan-20-one determined with an intravenous EEG-threshold method in male rats. Pharmacol. Toxicol. 61: 42-47. Beauchamp, M.H. et al. 2000 Neurosteroids and reward: allopregnanolone produces a conditioned place aversion in rats. Pharmacol. Biochem. Behav. 67: 29-35. Björn, I. et al. 2002. The impact of different doses of medroxyprogesterone acetate on mood symptoms in sequential hormonal therapy. Gynecol. Endocrinol. 16: 1-8. Graham, C.A. & B.B. Sherwin. 1987. The relationship between retrospective premenstrual symptom reporting and present oral contraceptive use. J. Psychosom. Res. 31: 45-53. Gulinello, M. et al. 2001. Short-term exposure to a neuroactive steroid increases alpha4 GABA(A) receptor subunit levels in association with increased anxiety in the female rat. Brain Res. 910: 55-66. Charette, L. et al. 1990. Alcohol consumption and menstrual distress in women at higher and lower risk for alcoholism. Alcohol Clin. Exp. Res. 14: 152-157. Muse, K.N. et al. 1984. The premenstrual syndrome: effects of "medical ovariectomy." N. Engl. J. Med. 311: 1345-1349. Kouri, E.M. & U. Halbreich. 1997. State and trait serotonergic abnormalities in women with dysphoric premenstrual syndromes. Psychopharmacol. Bull. 33: 767-770. Bäckström, T. et al. 1983 Endocrinological aspects on cyclical mood changes or the premenstrual syndrome. J. Psychosom. Obstet. Gynecol. 2: 8-20 Masia, S.L. et al. 2000. Emotional outbursts and post-traumatic stress disorder during intracarotid amobarbital procedure. Neurology 54: 1691-1693. Sveinsdottir, H. & T. Bäckström. 2000. Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives. Acta Obstet. Gynecol. Scand. 79: 405-413. Laidlaw, J. 1956 Catamenial epilepsy. Lancet 271: 1235-1237. Marshall, F.H. et al. 1997. Development of tolerance in mice to the sedative effects of the neuroactive steroid minaxolone following chronic exposure. Pharmacol. Biochem. Behav. 58: 1-8. Grant, K.A. et al. 1996. Ethanol-like discriminative stimulus effects of the neurosteroid 3 alpha-hydroxy-5 alpha-pregnan-20-one in female Macaca fascicularis monkeys. Psychopharmacology 124: 340-346. Bäckström, T. et al. 2003. The role of hormones and hormonal treatments in premenstrual syndrome. CNS Drugs 17: 325-342. Gasior, M. et al. 1997. Anticonvulsant and behavioral effects of neuroactive steroids alone and in conjunction with diazepam. J. Pharmacol. Exp. Ther. 282: 543-553. Tobin, M.B. et al. 1994. Reported alcohol use in women with premenstrual syndrome, Am. J. Psychiatry 151: 1503-1504. Dhar, V. & B.E. Murphy 1990. Double-blind randomized crossover trial of luteal phase estrogens (Premarin) in the premenstrual syndrome (PMS). Psychoneuroendocrinology 15: 489-493. Yu, R. et al. 1996. Down-regulation of the GABA receptor subunits mRNA levels in mammalian cultured cortical neurons following chronic neurosteroid treatment. Brain Res. Mol. Brain Res. 41: 163-168. Wang, M. et al. 1996. Relationship between symptom severity and steroid variation in women with premenstrual syndrome: Study on serum pregnenolone, pregnenolone sulfate, 5 alpha-pregnane-3,20-dione and 3 alpha-hydroxy-5alpha-pregnan-20-one. J. Clin. Endocrinol. Metab. 81: 1076-1082. Bitran, D. et al. 1991. Anxiolytic effects of 3 alpha-hydroxy-5 alpha[beta]-pregnan-20-one: endogenous metabolites of progesterone that are active at the GABAA receptor. Brain Res. 561: 157-161. Sundström, I. et al. 1997. Reduced benzodiazepine sensitivity in patients with premenstrual syndrome: a pilot study. Psychoneuroendocrinology 22: 25-38. Kurthen, M. et al. 1991. Severe negative emotional reactions in intracarotid sodium amytal procedures: further evidence for hemispheric asymmetries Cortex 27: 333-337. Björn, I. et al. 2000. Negative mood changes during hormone replacement therapy: a comparison between two progestogens. Am. J. Obstet. Gynecol. 183: 1419-1426. Hammarbäck, S. et al. 1991. Spontaneous anovulation causing disappearance of cyclical symptoms in women with the premenstrual syndrome. Acta Endocrinol. 125: 132-137. Majewska, M.D. et al. 1986. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 232: 1004-1007. Purdy, R.H. et al. 1990. Radioimmunoassay of 3alpha-hydroxy-5alpha-pregnan-20-one in rat and human plasma. Steroids 55: 290-296. Sibille, E. et al. 2000. Genetic inactivation of the serotonin 1 α receptor in mice results in downregulation of major GABA-A receptor α subunits: reduction of GABA-A receptor binding, and benzodiazepine-resistant anxiety. J. Neurosci. 20: 2758-2765. Parks, C.L. et al. 1998. Increased anxiety of mice lacking the serotonin 1 α receptor. Proc. Natl. Acad. Sci. USA 95: 10734-10739. Bäckström, T. et al. 1986. The human corpus luteum secretes 5alpha-pregnane-3,20-dione. Acta Endocrinol. (Copenh.) 111: 116-121. Österlund, M.K. et al. 2000. Estrogen receptor beta (ERbeta) messenger ribonucleic acid (mRNA) expression within the human forebrain: distinct distribution pattern to ERalpha mRNA. J. Clin. Endocrinol. Metab. 85: 3840-3846. Wenzel, R.R. et al. 2002. Central-nervous side effects of midazolam during transesophageal echocardiography. J. Am. Soc. Echocardiogr. 15: 1297-1300. Khisti, R.T. et al. 1998. The neurosteroid 3 alpha-hydroxy-5 alpha-pregnan-20-one induces catalepsy in mice. Neurosci. Lett. 251: 85-88. Andréen, L. et al. 2003. Progesterone effects during hormone replacement therapy. Eur. J. Endocrinol. 148: 571-577. Sundström, I. & T. Bäckström. 1998. Citalopram increases pregnanolone sensitivity in patients with premenstrual syndrome: an open trial. Psychoneuroendocrinology 23: 73-88. Freeman, E.W. et al. 2002. Allopregnanolone levels and symptom improvement in severe premenstrual syndrome. J. Clin. Psychopharmacol. 22: 516-520. Hallbreich, U. et al. 1993. Menstrually related disorders: points of consensus, debate, and disagreement. Neuropsychopharmacology 9: 13-15. Seippe, I. L. & T. Bäckström. 1998. Luteal phase estradiol relates to symptom severity between patients with premenstrual syndrome. J. Clin. Endocrinol. Metab. 83: 1988-1992. Sundström, I. et al. 1997. Patients with premenstrual syndrome have reduced sensitivity to midazolam compared to control subjects. Neuropsychopharmacology 17: 370-381. McLeod, D.R. et al. 1994. Family history of alcoholism in women with generalized anxiety disorder who have premenstrual syndrome: patient reports of premenstrual alcohol consumption and symptoms of anxiety, Alcohol Clin. Exp. Res. 18: 664-670. Smith, S.S. et al. 1998. GABA(A) receptor alpha4 subunit suppression prevents withdrawal properties of an endogenous steroid. Nature 392: 926-930. Wang, M. et al. 2001. Neuroactive steroids and central nervous system disorders. Int. Rev. Neurobiol. 46: 421-459. Fish, E.W. et al. 2001. Alcohol, allopregnanolone and aggression in mice. Psychopharmacology (Berl.) 153: 473-483. Hammarbäck, S. et al. 1989. Relationship between symptom severity and hormone changes in women with premenstrual syndrome. J. Clin. Endocrinol. Metab. 68: 125-130. Sundstrom, I. et al. 1999. Treatment of premenstrual syndrome with gonadotropin-releasing hormone agonist in a low dose regimen. Acta Obstet. Gynecol. Scand. 78: 891-899. Purdy, R.H. et al. 1991. Stress-induced elevations of gamma-aminobutyric acid type A receptor-active steroids in the rat brain. Proc. Natl. Acad. Sci. USA 88: 4553-4557. Sundström, I. 1998. Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects. Neuroendocrinology 67: 126-138. Grunewald, R.A. et al. 1992. Exacerbation of typical absence seizures by progesterone. Seizure 1: 137-138. McEwen, B.S. 1991. Non-genomic and genomic effects of steroids on neural activity. Trends Pharmacol. Sci. 12: 141-147. Bäckström, T. et al. 1983. Mood, sexuality, hormones and the menstrual cycle. II. Hormone levels and their relationship to premenstrual syndrome. Psychosom. Med. 45: 503-507. Herzog, A.G. et al. 1997. Three patterns of catamenial epilepsy. Epilepsia 38: 1082-1088. Harrison, N.L. & M.A. Simmonds. 1984. Modulation of the GABA receptor complex by a steroid anaesthetic. Brain Res. 323: 287-292. MacGregor, E.A. 1996. "Menstrual" migraine: towards a definition. Cephalalgia 16: 11-21. Hammarbäck, S. et al. 1985. Cyclical mood changes as in the premenstrual tension syndrome during sequential estrogen-progestagen postmenopausal replacement treatment. Acta Obstet. Gynecol. Scand. 64: 393-397. Landgren, S. et al. 1987. The effect of progesterone and its metabolites on the interictal epileptiform discharge in the cat's cerebral cortex. Acta Physiol Scand 131: 33-42. Bixo, M. et al. 1997. Progesterone, 5alpha-pregnane-3,20-dione and 3alpha-hydroxy-5alpha-pregnane-20-one in specific regions of the human female brain in different endocrine states. Brain Res. 764: 173-178. Paul, S.M. & RH. Purdy. 1992. Neuroactive steroids. FASEB J. 6: 2311-2322. Wooley, D.E. & P.S. Timiras. 1962. The gonad-brain relationship: effects of female sex hormones on electro-shock convulsions in the rat. Endocrinology 70: 196-209. Bixo, M. et al. 1995. Estradiol and testosterone in specific regions of the human female brain in different endocrine states. J. Steroid Biochem. Mol. Biol. 55: 297-303. Lee, G.P. et al. 1988. Severe behavioral complications following intracarotid sodium amobarbital injection: implications for hemispheric asymmetry of emotion. Neurology 38: 1233-1236. Banerjee, P.K. & O.C. Snerd, III. 1998. Neuroactive steroids exacerbate gamma-hydroxybutyric acid-induced absence seizures in rats. Eur. J. Pharmacol. 359: 41-48. Nyberg, S. et al. 2003. Sensitivity to alcohol among patients with premenstrual dysphoric disorder. Psychoneuroendocrinology. In press. Mok, W.M. & N.R. 2002; 16 1993; 9 2002; 15 1990; 55 1987; 31 1990; 14 1983; 2 1984; 323 1991; 12 1990; 15 2000; 85 1988; 38 1959; 9 2003; 17 1998; 359 1998; 83 2001; 46 1985; 64 1962; 70 1998; 392 1992; 6 1956; 271 1990; 45 1990; 533 1984; 311 1991; 88 2000; 54 1997; 58 1997; 13 1998; 807 1997; 56 1997; 17 1999; 55 1998; 95 1992; 1 2003; 88 1994; 32 1997; 22 2000; 67 1986; 232 1986; 111 1995; 55 1994; 151 2000; 20 1994; 89 1998; 338 2001; 26 2003 2002; 934 1996; 16 1996; 124 1989; 68 1998; 67 1998; 23 1994; 84 1996; 53 1972; 236 1998; 251 1976; 54 1991; 561 1987; 131 1997; 764 1991; 27 1991; 125 2001; 153 1997; 33 1987; 61 1997; 282 2000; 79 1993; 11 2000; 75 2002; 22 1999; 78 2000; 183 1988; 475 1996; 41 1997; 38 1996; 81 1994; 18 2003; 148 2001; 910 1998; 6 1983; 45 Klaiber E.L. (e_1_2_12_77_2) 1997; 22 e_1_2_12_4_2 e_1_2_12_19_2 e_1_2_12_15_2 e_1_2_12_38_2 e_1_2_12_59_2 e_1_2_12_41_2 e_1_2_12_64_2 e_1_2_12_20_2 e_1_2_12_43_2 e_1_2_12_62_2 e_1_2_12_85_2 e_1_2_12_22_2 e_1_2_12_45_2 e_1_2_12_68_2 e_1_2_12_24_2 e_1_2_12_47_2 e_1_2_12_66_2 e_1_2_12_89_2 Bäckström T. (e_1_2_12_2_2) 1983; 45 e_1_2_12_60_2 e_1_2_12_83_2 e_1_2_12_26_2 e_1_2_12_49_2 e_1_2_12_28_2 e_1_2_12_52_2 e_1_2_12_75_2 e_1_2_12_73_2 e_1_2_12_33_2 e_1_2_12_56_2 e_1_2_12_79_2 e_1_2_12_35_2 e_1_2_12_14_2 Chan A.F. (e_1_2_12_17_2) 1994; 84 e_1_2_12_12_2 e_1_2_12_10_2 e_1_2_12_71_2 e_1_2_12_6_2 e_1_2_12_50_2 Nyberg S. (e_1_2_12_54_2) 2003 e_1_2_12_8_2 e_1_2_12_3_2 e_1_2_12_5_2 e_1_2_12_18_2 e_1_2_12_16_2 e_1_2_12_37_2 e_1_2_12_39_2 Tobin M.B. (e_1_2_12_58_2) 1994; 151 Cullberg J. (e_1_2_12_81_2) 1972; 236 e_1_2_12_40_2 e_1_2_12_65_2 e_1_2_12_86_2 e_1_2_12_21_2 Gasior M. (e_1_2_12_31_2) 1997; 282 e_1_2_12_42_2 e_1_2_12_63_2 e_1_2_12_44_2 e_1_2_12_69_2 e_1_2_12_25_2 e_1_2_12_46_2 e_1_2_12_67_2 e_1_2_12_88_2 e_1_2_12_61_2 e_1_2_12_82_2 e_1_2_12_80_2 Sibille E. (e_1_2_12_87_2) 2000; 20 e_1_2_12_27_2 e_1_2_12_48_2 e_1_2_12_29_2 e_1_2_12_30_2 e_1_2_12_51_2 e_1_2_12_76_2 e_1_2_12_32_2 e_1_2_12_53_2 e_1_2_12_74_2 e_1_2_12_34_2 e_1_2_12_55_2 Kouri E.M. (e_1_2_12_84_2) 1997; 33 e_1_2_12_36_2 e_1_2_12_57_2 e_1_2_12_78_2 e_1_2_12_13_2 Bäckström T. (e_1_2_12_23_2) 1986; 111 e_1_2_12_11_2 e_1_2_12_7_2 e_1_2_12_72_2 e_1_2_12_9_2 e_1_2_12_70_2 |
References_xml | – volume: 45 start-page: 189 year: 1990 end-page: 197 article-title: Emulsion: a preliminary pharmacokinetic and pharmacodynamic study of a new intravenous anaesthetic agent publication-title: Anaesthesia – volume: 16 start-page: 11 year: 1996 end-page: 21 article-title: “Menstrual” migraine: towards a definition publication-title: Cephalalgia – volume: 323 start-page: 287 year: 1984 end-page: 292 article-title: Modulation of the GABA receptor complex by a steroid anaesthetic publication-title: Brain Res. – volume: 38 start-page: 1082 year: 1997 end-page: 1088 article-title: Three patterns of catamenial epilepsy publication-title: Epilepsia – volume: 910 start-page: 55 year: 2001 end-page: 66 article-title: Short‐term exposure to a neuroactive steroid increases alpha4 GABA(A) receptor subunit levels in association with increased anxiety in the female rat publication-title: Brain Res. – volume: 23 start-page: 73 year: 1998 end-page: 88 article-title: Citalopram increases pregnanolone sensitivity in patients with premenstrual syndrome: an open trial publication-title: Psychoneuroendocrinology – volume: 131 start-page: 33 year: 1987 end-page: 42 article-title: The effect of progesterone and its metabolites on the interictal epileptiform discharge in the cat's cerebral cortex publication-title: Acta Physiol Scand – volume: 9 start-page: 352 year: 1959 end-page: 360 article-title: The role of estrogens in catamenial exacerbation of epilepsy publication-title: Neurology – volume: 16 start-page: 1 year: 2002 end-page: 8 article-title: The impact of different doses of medroxyprogesterone acetate on mood symptoms in sequential hormonal therapy publication-title: Gynecol. Endocrinol. – volume: 934 start-page: 125 year: 2002 end-page: 131 article-title: Allopregnanolone inhibits learning in the Morris water maze publication-title: Brain Res. – volume: 38 start-page: 1233 year: 1988 end-page: 1236 article-title: Severe behavioral complications following intracarotid sodium amobarbital injection: implications for hemispheric asymmetry of emotion publication-title: Neurology – volume: 15 start-page: 489 year: 1990 end-page: 493 article-title: Double‐blind randomized crossover trial of luteal phase estrogens (Premarin) in the premenstrual syndrome (PMS) publication-title: Psychoneuroendocrinology – volume: 33 start-page: 767 year: 1997 end-page: 770 article-title: State and trait serotonergic abnormalities in women with dysphoric premenstrual syndromes publication-title: Psychopharmacol. Bull. – volume: 14 start-page: 152 year: 1990 end-page: 157 article-title: Alcohol consumption and menstrual distress in women at higher and lower risk for alcoholism publication-title: Alcohol Clin. Exp. Res. – volume: 75 start-page: 1390 year: 2000 end-page: 1397 article-title: The human brain has distinct regional expression patterns of estrogen receptor alpha mRNA isoforms derived from alternative promoters publication-title: J. Neurochem. – volume: 79 start-page: 405 year: 2000 end-page: 413 article-title: Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives publication-title: Acta Obstet. Gynecol. Scand. – volume: 18 start-page: 664 year: 1994 end-page: 670 article-title: Family history of alcoholism in women with generalized anxiety disorder who have premenstrual syndrome: patient reports of premenstrual alcohol consumption and symptoms of anxiety publication-title: Alcohol Clin. Exp. Res. – volume: 125 start-page: 132 year: 1991 end-page: 137 article-title: Spontaneous anovulation causing disappearance of cyclical symptoms in women with the premenstrual syndrome publication-title: Acta Endocrinol. – volume: 58 start-page: 1 year: 1997 end-page: 8 article-title: Development of tolerance in mice to the sedative effects of the neuroactive steroid minaxolone following chronic exposure publication-title: Pharmacol. Biochem. Behav. – volume: 807 start-page: 84 year: 1998 end-page: 90 article-title: Progesterone withdrawal I: pro‐convulsant effects publication-title: Brain Res. – volume: 311 start-page: 1345 year: 1984 end-page: 1349 article-title: The premenstrual syndrome: effects of “medical ovariectomy.” publication-title: N. Engl. J. Med. – volume: 236 start-page: 1 issue: Suppl. year: 1972 end-page: 84 article-title: Mood changes and menstrual symptoms with different gestagen/estrogen combinations: a double blind comparison with placebo publication-title: Acta Psychiat. Scand. – volume: 17 start-page: 370 year: 1997 end-page: 381 article-title: Patients with premenstrual syndrome have reduced sensitivity to midazolam compared to control subjects publication-title: Neuropsychopharmacology – volume: 84 start-page: 1001 year: 1994 end-page: 1005 article-title: Persistence of premenstrual syndrome during low‐dose administration of the progesterone antagonist RU 486 publication-title: Obstet. Gynecol. – year: 2003 article-title: Sensitivity to alcohol among patients with premenstrual dysphoric disorder publication-title: Psychoneuroendocrinology – volume: 251 start-page: 85 year: 1998 end-page: 88 article-title: The neurosteroid 3 alpha‐hydroxy‐5 alpha‐pregnan‐20‐one induces catalepsy in mice publication-title: Neurosci. Lett. – volume: 13 start-page: 139 year: 1997 end-page: 171 article-title: Alcohol, GABAA‐benzodiazepine receptor complex, and aggression publication-title: Recent Dev. Alcohol – volume: 764 start-page: 173 year: 1997 end-page: 178 article-title: Progesterone, 5alpha‐pregnane‐3,20‐dione and 3alpha‐hydroxy‐5alpha‐pregnane‐20‐one in specific regions of the human female brain in different endocrine states publication-title: Brain Res. – volume: 22 start-page: 549 year: 1997 end-page: 58 article-title: Relationships of serum estradiol levels publication-title: menopausal duration and mood during hormonal replacement therapy. Psychoneuroendocrinology – volume: 61 start-page: 42 year: 1987 end-page: 47 article-title: The anaesthetic potency of 3 alpha‐hydroxy‐5 alpha‐pregnan‐20‐one and 3 alpha‐hydroxy‐5 beta‐pregnan‐20‐one determined with an intravenous EEG‐threshold method in male rats publication-title: Pharmacol. Toxicol. – volume: 22 start-page: 516 year: 2002 end-page: 520 article-title: Allopregnanolone levels and symptom improvement in severe premenstrual syndrome publication-title: J. Clin. Psychopharmacol. – volume: 151 start-page: 1503 year: 1994 end-page: 1504 article-title: Reported alcohol use in women with premenstrual syndrome, Am publication-title: J. Psychiatry – volume: 81 start-page: 1076 year: 1996 end-page: 1082 article-title: Relationship between symptom severity and steroid variation in women with premenstrual syndrome: Study on serum pregnenolone, pregnenolone sulfate, 5 alpha‐pregnane‐3,20‐dione and 3 alpha‐hydroxy‐5alpha‐pregnan‐20‐one publication-title: J. Clin. Endocrinol. Metab. – volume: 20 start-page: 2758 year: 2000 end-page: 2765 article-title: Genetic inactivation of the serotonin 1 α receptor in mice results in downregulation of major GABA‐A receptor α subunits: reduction of GABA‐A receptor binding, and benzodiazepine‐resistant anxiety publication-title: J. Neurosci. – volume: 88 start-page: 2026 year: 2003 end-page: 2030 article-title: Increase of estrogen dose deteriorates mood during progestin phase in sequential hormonal therapy publication-title: J. Clin. Endocrinol. Metab. – volume: 55 start-page: 125 year: 1999 end-page: 130 article-title: Lack of influence of menstrual cycle and premenstrual syndrome diagnosis on pregnanolone pharmacokinetics publication-title: Eur. J. Clin. Pharmacol. – volume: 55 start-page: 290 year: 1990 end-page: 296 article-title: Radioimmunoassay of 3alpha‐hydroxy‐5alpha‐pregnan‐20‐one in rat and human plasma publication-title: Steroids – volume: 359 start-page: 41 year: 1998 end-page: 48 article-title: Neuroactive steroids exacerbate gamma‐hydroxybutyric acid‐induced absence seizures in rats publication-title: Eur. J. Pharmacol. – volume: 46 start-page: 421 year: 2001 end-page: 459 article-title: Neuroactive steroids and central nervous system disorders publication-title: Int. Rev. Neurobiol. – volume: 31 start-page: 45 year: 1987 end-page: 53 article-title: The relationship between retrospective premenstrual symptom reporting and present oral contraceptive use publication-title: J. Psychosom. Res. – volume: 17 start-page: 1848 year: 1997 end-page: 1859 article-title: Estradiol increases the sensitivity of hippocampal CA1 pyramidal cells to NMDA receptor‐mediated synaptic input: correlation with dendritic spine density publication-title: J. Neurosci. – volume: 111 start-page: 116 year: 1986 end-page: 121 article-title: The human corpus luteum secretes 5alpha‐pregnane‐3,20‐dione publication-title: Acta Endocrinol. (Copenh.) – volume: 153 start-page: 473 year: 2001 end-page: 483 article-title: Alcohol, allopregnanolone and aggression in mice publication-title: Psychopharmacology (Berl.) – volume: 17 start-page: 325 year: 2003 end-page: 342 article-title: The role of hormones and hormonal treatments in premenstrual syndrome publication-title: CNS Drugs – volume: 271 start-page: 1235 year: 1956 end-page: 1237 article-title: Catamenial epilepsy publication-title: Lancet – volume: 68 start-page: 125 year: 1989 end-page: 130 article-title: Relationship between symptom severity and hormone changes in women with premenstrual syndrome publication-title: J. Clin. Endocrinol. Metab. – volume: 83 start-page: 1988 year: 1998 end-page: 1992 article-title: Luteal phase estradiol relates to symptom severity between patients with premenstrual syndrome publication-title: J. Clin. Endocrinol. Metab. – volume: 54 start-page: 321 year: 1976 end-page: 347 article-title: Epileptic seizures in women related to plasma estrogen and progesterone during the menstrual cycle publication-title: Acta Neurol. Scand. – volume: 89 start-page: 1455 year: 1994 end-page: 1459 article-title: The benzodiazepine withdrawal syndrome publication-title: Addiction – volume: 32 start-page: 37 year: 1994 end-page: 44 article-title: Acute tryptophan depletion aggravates premenstrual syndrome publication-title: J. Affect. Disord. – volume: 54 start-page: 1691 year: 2000 end-page: 1693 article-title: Emotional outbursts and post‐traumatic stress disorder during intracarotid amobarbital procedure publication-title: Neurology – volume: 6 start-page: 2311 year: 1992 end-page: 2322 article-title: Neuroactive steroids publication-title: FASEB J. – volume: 124 start-page: 340 year: 1996 end-page: 346 article-title: Ethanol‐like discriminative stimulus effects of the neurosteroid 3 alpha‐hydroxy‐5 alpha‐pregnan‐20‐one in female monkeys publication-title: Psychopharmacology – volume: 85 start-page: 3840 year: 2000 end-page: 3846 article-title: Estrogen receptor beta (ERbeta) messenger ribonucleic acid (mRNA) expression within the human forebrain: distinct distribution pattern to ERalpha mRNA publication-title: J. Clin. Endocrinol. Metab. – volume: 561 start-page: 157 year: 1991 end-page: 161 article-title: Anxiolytic effects of 3 alpha‐hydroxy‐5 alpha[beta]‐pregnan‐20‐one: endogenous metabolites of progesterone that are active at the GABAA receptor publication-title: Brain Res. – volume: 64 start-page: 393 year: 1985 end-page: 397 article-title: Cyclical mood changes as in the premenstrual tension syndrome during sequential estrogen‐progestagen postmenopausal replacement treatment publication-title: Acta Obstet. Gynecol. Scand. – volume: 22 start-page: 25 year: 1997 end-page: 38 article-title: Reduced benzodiazepine sensitivity in patients with premenstrual syndrome: a pilot study publication-title: Psychoneuroendocrinology – volume: 12 start-page: 141 year: 1991 end-page: 147 article-title: Non‐genomic and genomic effects of steroids on neural activity publication-title: Trends Pharmacol. Sci. – volume: 27 start-page: 333 year: 1991 end-page: 337 article-title: Severe negative emotional reactions in intracarotid sodium amytal procedures: further evidence for hemispheric asymmetries publication-title: Cortex – volume: 41 start-page: 163 year: 1996 end-page: 168 article-title: Down‐regulation of the GABA receptor subunits mRNA levels in mammalian cultured cortical neurons following chronic neurosteroid treatment publication-title: Brain Res. Mol. Brain Res. – volume: 95 start-page: 10734 year: 1998 end-page: 10739 article-title: Increased anxiety of mice lacking the serotonin 1 α receptor publication-title: Proc. Natl. Acad. Sci. USA – volume: 282 start-page: 543 year: 1997 end-page: 553 article-title: Anticonvulsant and behavioral effects of neuroactive steroids alone and in conjunction with diazepam publication-title: J. Pharmacol. Exp. Ther. – volume: 232 start-page: 1004 year: 1986 end-page: 1007 article-title: Steroid hormone metabolites are barbiturate‐like modulators of the GABA receptor publication-title: Science – volume: 26 start-page: 551 year: 2001 end-page: 564 article-title: Binding of [3H]paroxetine to serotonin uptake sites and of [3H]lysergic acid diethylamide to 5‐HT2A receptors in platelets from women with premenstrual dysphoric disorder during gonadotropin releasing hormone treatment publication-title: Psychoneuroendocrinology – volume: 53 start-page: 777 year: 1996 end-page: 782 article-title: The hyperphagic effect of 3 alpha‐hydroxylated pregnane steroids in male rats publication-title: Pharmacol. Biochem. Behav. – volume: 11 start-page: 170 year: 1993 end-page: 179 article-title: Alcohol, benzodiazepine‐GABAa receptor complex and aggression: ethological analysis of individual differences in rodents and primates publication-title: J. Stud. Alcohol – volume: 475 start-page: 272 year: 1988 end-page: 282 article-title: Locally applied estrogens potentiate glutamate‐evoked excitation of cerebellar Purkinje cells publication-title: Brain Res. – volume: 183 start-page: 1419 year: 2000 end-page: 1426 article-title: Negative mood changes during hormone replacement therapy: a comparison between two progestogens publication-title: Am. J. Obstet. Gynecol. – volume: 338 start-page: 209 year: 1998 end-page: 216 article-title: Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome publication-title: N. Engl. J. Med. – volume: 56 start-page: 261 year: 1997 end-page: 264 article-title: Rewarding effect of the neuroactive steroid 3 alpha‐hydroxy‐5 alpha‐pregnan‐20‐one in mice publication-title: Pharmacol. Biochem. Behav. – volume: 533 start-page: 42 year: 1990 end-page: 45 article-title: Evidence that 5 alpha‐pregnan‐3 alpha‐ol‐20‐one is the metabolite responsible for progesterone anesthesia publication-title: Brain Res. – volume: 55 start-page: 297 year: 1995 end-page: 303 article-title: Estradiol and testosterone in specific regions of the human female brain in different endocrine states publication-title: J. Steroid Biochem. Mol. Biol. – volume: 9 start-page: 13 year: 1993 end-page: 15 article-title: Menstrually related disorders: points of consensus, debate, and disagreement publication-title: Neuropsychopharmacology – volume: 392 start-page: 926 year: 1998 end-page: 930 article-title: GABA(A) receptor alpha4 subunit suppression prevents withdrawal properties of an endogenous steroid publication-title: Nature – volume: 15 start-page: 1297 year: 2002 end-page: 1300 article-title: Central‐nervous side effects of midazolam during transesophageal echocardiography publication-title: J. Am. Soc. Echocardiogr. – volume: 2 start-page: 8 year: 1983 end-page: 20 article-title: Endocrinological aspects on cyclical mood changes or the premenstrual syndrome publication-title: J. Psychosom. Obstet. Gynecol. – volume: 95 start-page: 13284 year: 1998 end-page: 13289 article-title: Role of brain allopregnanolone in the plasticity of gamma‐aminobutyric acid type A receptor in rat brain during pregnancy and after delivery publication-title: Proc. Natl. Acad. Sci. USA – volume: 78 start-page: 891 year: 1999 end-page: 899 article-title: Treatment of premenstrual syndrome with gonadotropin‐releasing hormone agonist in a low dose regimen publication-title: Acta Obstet. Gynecol. Scand. – volume: 6 start-page: 5 year: 1998 end-page: 22 article-title: Cyclicity affects pain and other symptoms in female fibromyalgia syndrome patients publication-title: J. Muscularskeletal Pain – volume: 45 start-page: 503 year: 1983 end-page: 507 article-title: Mood, sexuality, hormones and the menstrual cycle publication-title: II. Hormone levels and their relationship to premenstrual syndrome. Psychosom. Med. – volume: 1 start-page: 137 year: 1992 end-page: 138 article-title: Exacerbation of typical absence seizures by progesterone publication-title: Seizure – volume: 88 start-page: 4553 year: 1991 end-page: 4557 article-title: Stress‐induced elevations of gamma‐aminobutyric acid type A receptor‐active steroids in the rat brain publication-title: Proc. Natl. Acad. Sci. USA – volume: 70 start-page: 196 year: 1962 end-page: 209 article-title: The gonad‐brain relationship: effects of female sex hormones on electro‐shock convulsions in the rat publication-title: Endocrinology – volume: 67 start-page: 29 year: 2000 end-page: 35 article-title: Neurosteroids and reward: allopregnanolone produces a conditioned place aversion in rats publication-title: Pharmacol. Biochem. Behav. – volume: 67 start-page: 126 year: 1998 end-page: 138 article-title: Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects publication-title: Neuroendocrinology – volume: 148 start-page: 571 year: 2003 end-page: 577 article-title: Progesterone effects during hormone replacement therapy publication-title: Eur. J. Endocrinol. – volume: 20 start-page: 2758 year: 2000 ident: e_1_2_12_87_2 article-title: Genetic inactivation of the serotonin 1 α receptor in mice results in downregulation of major GABA‐A receptor α subunits: reduction of GABA‐A receptor binding, and benzodiazepine‐resistant anxiety publication-title: J. Neurosci. doi: 10.1523/JNEUROSCI.20-08-02758.2000 contributor: fullname: Sibille E. – ident: e_1_2_12_50_2 doi: 10.1016/0169-328X(96)00087-3 – ident: e_1_2_12_86_2 doi: 10.1016/S0306-4530(01)00010-5 – ident: e_1_2_12_55_2 doi: 10.1007/BF02247439 – ident: e_1_2_12_80_2 doi: 10.2165/00023210-200317050-00003 – ident: e_1_2_12_67_2 doi: 10.1530/acta.0.1250132 – ident: e_1_2_12_36_2 doi: 10.1016/1059-1311(92)90012-P – volume: 111 start-page: 116 year: 1986 ident: e_1_2_12_23_2 article-title: The human corpus luteum secretes 5alpha‐pregnane‐3,20‐dione publication-title: Acta Endocrinol. (Copenh.) contributor: fullname: Bäckström T. – ident: e_1_2_12_39_2 doi: 10.1212/WNL.54.8.1691 – ident: e_1_2_12_75_2 doi: 10.1056/NEJM199801223380401 – volume: 236 start-page: 1 year: 1972 ident: e_1_2_12_81_2 article-title: Mood changes and menstrual symptoms with different gestagen/estrogen combinations: a double blind comparison with placebo publication-title: Acta Psychiat. Scand. contributor: fullname: Cullberg J. – ident: e_1_2_12_9_2 doi: 10.1210/jc.85.10.3840 – ident: e_1_2_12_56_2 doi: 10.1111/j.1530-0277.1990.tb00462.x – ident: e_1_2_12_40_2 doi: 10.1007/0-306-47141-8_9 – ident: e_1_2_12_4_2 doi: 10.1016/S0140-6736(56)90003-4 – ident: e_1_2_12_16_2 doi: 10.1523/JNEUROSCI.17-05-01848.1997 – ident: e_1_2_12_60_2 doi: 10.1300/J094v06n04_02 – ident: e_1_2_12_68_2 doi: 10.3109/00016348809004191 – ident: e_1_2_12_21_2 doi: 10.1210/jc.81.3.1076 – ident: e_1_2_12_27_2 doi: 10.1159/000054307 – ident: e_1_2_12_35_2 doi: 10.1016/S0014-2999(98)00629-3 – ident: e_1_2_12_88_2 doi: 10.1073/pnas.95.18.10734 – ident: e_1_2_12_28_2 doi: 10.1111/j.1600-0773.1987.tb01770.x – ident: e_1_2_12_48_2 doi: 10.1080/713602990 – ident: e_1_2_12_70_2 doi: 10.1097/00004714-200210000-00013 – ident: e_1_2_12_13_2 doi: 10.1016/0006-8993(90)91792-F – ident: e_1_2_12_34_2 doi: 10.1016/S0304-3940(98)00479-0 – ident: e_1_2_12_8_2 doi: 10.1046/j.1471-4159.2000.0751390.x – ident: e_1_2_12_12_2 doi: 10.1016/0165-6147(91)90531-V – ident: e_1_2_12_46_2 doi: 10.1016/S0010-9452(13)80139-6 – volume: 151 start-page: 1503 year: 1994 ident: e_1_2_12_58_2 article-title: Reported alcohol use in women with premenstrual syndrome, Am publication-title: J. Psychiatry contributor: fullname: Tobin M.B. – ident: e_1_2_12_10_2 doi: 10.1016/0006-8993(84)90299-3 – ident: e_1_2_12_32_2 doi: 10.1016/S0006-8993(02)02414-9 – ident: e_1_2_12_11_2 doi: 10.1126/science.2422758 – ident: e_1_2_12_37_2 doi: 10.1016/S0091-3057(96)00218-3 – ident: e_1_2_12_22_2 doi: 10.1016/0039-128X(90)90031-6 – ident: e_1_2_12_59_2 doi: 10.1111/j.1360-0443.1994.tb03743.x – ident: e_1_2_12_66_2 doi: 10.1016/S0074-7742(01)46071-5 – ident: e_1_2_12_79_2 doi: 10.1210/jc.83.6.1988 – ident: e_1_2_12_42_2 doi: 10.1016/S0006-8993(01)02565-3 – ident: e_1_2_12_45_2 doi: 10.15288/jsas.1993.s11.170 – ident: e_1_2_12_57_2 doi: 10.1111/j.1530-0277.1994.tb00928.x – ident: e_1_2_12_5_2 doi: 10.1111/j.1600-0404.1976.tb04363.x – ident: e_1_2_12_6_2 doi: 10.1111/j.1528-1157.1997.tb01197.x – ident: e_1_2_12_51_2 doi: 10.1016/S0091-3057(96)00132-3 – ident: e_1_2_12_76_2 doi: 10.1016/0306-4530(90)90072-H – ident: e_1_2_12_26_2 doi: 10.1111/j.1365-2044.1990.tb14683.x – ident: e_1_2_12_44_2 doi: 10.1007/s002130000587 – ident: e_1_2_12_49_2 doi: 10.1530/eje.0.1480571 – ident: e_1_2_12_72_2 doi: 10.3109/00016348509155154 – ident: e_1_2_12_83_2 doi: 10.1016/S0893-133X(97)00086-9 – ident: e_1_2_12_14_2 doi: 10.1210/endo-70-2-196 – volume: 282 start-page: 543 year: 1997 ident: e_1_2_12_31_2 article-title: Anticonvulsant and behavioral effects of neuroactive steroids alone and in conjunction with diazepam publication-title: J. Pharmacol. Exp. Ther. contributor: fullname: Gasior M. – ident: e_1_2_12_38_2 doi: 10.1067/mje.2002.124572 – ident: e_1_2_12_85_2 doi: 10.1016/0165-0327(94)90059-0 – ident: e_1_2_12_89_2 doi: 10.1016/S0306-4530(97)00064-4 – ident: e_1_2_12_52_2 doi: 10.1073/pnas.95.22.13284 – ident: e_1_2_12_74_2 doi: 10.1210/jc.2002-020755 – volume: 22 start-page: 549 year: 1997 ident: e_1_2_12_77_2 article-title: Relationships of serum estradiol levels publication-title: menopausal duration and mood during hormonal replacement therapy. Psychoneuroendocrinology contributor: fullname: Klaiber E.L. – ident: e_1_2_12_25_2 doi: 10.1007/s002280050606 – ident: e_1_2_12_3_2 doi: 10.3109/01674828309081250 – ident: e_1_2_12_18_2 doi: 10.1073/pnas.88.10.4553 – volume: 33 start-page: 767 year: 1997 ident: e_1_2_12_84_2 article-title: State and trait serotonergic abnormalities in women with dysphoric premenstrual syndromes publication-title: Psychopharmacol. Bull. contributor: fullname: Kouri E.M. – volume: 84 start-page: 1001 year: 1994 ident: e_1_2_12_17_2 article-title: Persistence of premenstrual syndrome during low‐dose administration of the progesterone antagonist RU 486 publication-title: Obstet. Gynecol. contributor: fullname: Chan A.F. – ident: e_1_2_12_53_2 doi: 10.1016/S0306-4530(96)00035-2 – ident: e_1_2_12_61_2 doi: 10.1016/S0006-8993(98)00782-3 – ident: e_1_2_12_69_2 doi: 10.1056/NEJM198411223112104 – ident: e_1_2_12_24_2 doi: 10.1096/fasebj.6.6.1347506 – ident: e_1_2_12_78_2 doi: 10.1210/jcem-68-1-125 – ident: e_1_2_12_63_2 doi: 10.1212/WNL.9.5.352 – ident: e_1_2_12_41_2 doi: 10.1034/j.1600-0412.2000.079005405.x – volume: 45 start-page: 503 year: 1983 ident: e_1_2_12_2_2 article-title: Mood, sexuality, hormones and the menstrual cycle publication-title: II. Hormone levels and their relationship to premenstrual syndrome. Psychosom. Med. contributor: fullname: Bäckström T. – ident: e_1_2_12_30_2 doi: 10.1111/j.1748-1716.1987.tb08202.x – ident: e_1_2_12_19_2 doi: 10.1016/0960-0760(95)00179-4 – ident: e_1_2_12_29_2 doi: 10.1016/0006-8993(91)90761-J – ident: e_1_2_12_15_2 doi: 10.1016/0006-8993(88)90615-4 – ident: e_1_2_12_7_2 doi: 10.1046/j.1468-2982.1996.1601011.x – ident: e_1_2_12_47_2 doi: 10.1212/WNL.38.8.1233 – ident: e_1_2_12_71_2 doi: 10.1034/j.1600-0412.1999.781011.x – ident: e_1_2_12_73_2 doi: 10.1067/mob.2000.107781 – ident: e_1_2_12_62_2 doi: 10.1038/31948 – ident: e_1_2_12_65_2 – ident: e_1_2_12_20_2 doi: 10.1016/S0006-8993(97)00455-1 – ident: e_1_2_12_33_2 doi: 10.1016/0091-3057(95)02142-6 – ident: e_1_2_12_43_2 doi: 10.1016/S0091-3057(00)00299-9 – ident: e_1_2_12_64_2 doi: 10.1038/npp.1993.70 – ident: e_1_2_12_82_2 doi: 10.1016/0022-3999(87)90097-3 – year: 2003 ident: e_1_2_12_54_2 article-title: Sensitivity to alcohol among patients with premenstrual dysphoric disorder publication-title: Psychoneuroendocrinology contributor: fullname: Nyberg S. |
SSID | ssj0012847 |
Score | 2.1834857 |
SecondaryResourceType | review_article |
Snippet | : That 3alpha‐hydroxy‐5alpha/beta‐pregnane steroids (GABA steroids) have modulatory effects on the GABA‐A receptor is well known. In behavioral studies in... That 3alpha-hydroxy-5alpha/beta-pregnane steroids (GABA steroids) have modulatory effects on the GABA-A receptor is well known. In behavioral studies in... A bstract : That 3alpha‐hydroxy‐5alpha/beta‐pregnane steroids (GABA steroids) have modulatory effects on the GABA‐A receptor is well known. In behavioral... |
SourceID | swepub proquest crossref pubmed wiley istex |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 42 |
SubjectTerms | Affect - physiology allopregnanolone Animals epilepsy Female GABA Humans menstrual cycle Menstrual Cycle - physiology Mood Disorders - etiology Mood Disorders - physiopathology Mood Disorders - psychology Mood Disorders/etiology/physiopathology/psychology neurosteroid Pregnanolone - physiology premenstrual dysphoric disorder Premenstrual Syndrome - etiology Premenstrual Syndrome - physiopathology Premenstrual Syndrome - psychology Premenstrual Syndrome/etiology/physiopathology/psychology progesterone Receptors, GABA-A - physiology |
Title | Pathogenesis in Menstrual Cycle-Linked CNS Disorders |
URI | https://api.istex.fr/ark:/67375/WNG-SW743JX9-G/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1196%2Fannals.1286.005 https://www.ncbi.nlm.nih.gov/pubmed/14993039 https://search.proquest.com/docview/71539166 https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-16450 |
Volume | 1007 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bS8MwFD7oRPBFndd67YOKgtU1TVv7OOYNwTGY16eQNOkYYicrA_fmT_A3-ks8SbvKRBDB5yZpe77k5DtJzheAndgjriCx50jsPQ7FQg6nQjkBoR53pc9dodc7Ltth8-Hk9EzL5NRHuTC5PkS54KZHhvHXeoBzUdxCEhXqtgjQEfpXvZ2g08wxVjBJHF6r3EfQztf44hB9MXKZQtwHWzj-Vn9sXprSJn79iXSWiqLjZNbMRudz__Af8zBbUFG7nvedKkyodAGm88sphwtQLYZ9Zu8X2tQHixC0kDH2OtpBdjO7m9rXykjQYjuNIbby8fauo1sl7UazbY-kPbMluD0_u2lcOsXVC06sk3kRrzAWxBfcE8oTMVWJkJyExJeJ68YU4wweRFQiHePUjaWgRHJFgyRJkMFx5AHLUEl7qVoFG_mKG0oXa2M0xmMulPSiGpFJoBISBcSC_ZHh2UuusMFMZBKZbGm0DdO2YWgbC_YMMGU53n_SB9NCn903L1j7HunQ1UPELizYHiHHcLjoPRCeqt4gYyF6eGTEgQUrOaBf78TYD-fzyILdHOHyiVbgPu3e1Vmv32GD5wHDENOvWXBoYP3to1nzsd6mZO1vxddhJj82qA_ObEAFkVSbMJnJwZbp4Z8RZ_58 |
link.rule.ids | 230,315,782,786,887,1408,27933,27934,46064,46488 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwEB7xUFUuvFogPEoObUUlAsRxEnJcLY-FQoS0tMDJsmMHrRBZRLQS3PgJ_EZ-CTNONghUqULiHGeSzMvf2J4vAN-zgPmKZYGn0Xs8joM8yZXxIsYD6etQ-orWOzrdOD3f3tklmpymF6bih2gW3CgybL6mAKcF6SrKk5reFi20gQmW9hPCURjnEbojtXEEJ81OAqVfm41jzMaIZmp6HxSx-UbAq5lpnJR89y_Y2XCKvoazdj7am_qIL5mGyRqNuq3KfWZgxBSz8Kn6P-X9LMzUkV-6azU99a8vEJ0gaOxfUo7slW6vcI-NZaFFOe17lPL08EgFrtFuO-26Q3bP8iv82ds9bXe8-u8LXkb9vGiyOFMsVDJQJlAZN7nSksUs1LnvZxxLDRklXCMik9zPtOJMS8OjPM8RxEmEAnMwVvQLswAuQhY_1j7ejQWZzKQyOki2mM4jk7MkYg6sDTUvbiqSDWGLk8Q2TKNuBOlGoG4c-Gkt04yTt1d0Ni0OxVm6L7pniIgOzxOx78Dq0HQCI4a2QWRh-oNSxJjkERRHDsxXFn15JpZ_OKUnDvyoTNxcIRLund7flujfXorB9UBglRluObBu7fq_lxbpRavL2eL7hq_C587p8ZE4Okh_L8FEdYqQztEswxha1azAaKkH36y7PwMdBQKz |
linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3bTuMwEB1BESteuO0C4ZoHQKxEgDhOQh6rlnKPKnV3C0-WHTtVhUgRUSV44xP4Rr6EsZMGgVZCSDzHmSRzPOMzvpwAbCYecQVJPEdi73EoNnI4FcoJCPW4K33uCj3fcdIJ46vD5pGWyamPzsIU-hDVhJuODJOvdYDfybQI8qhUt0WA9jC_6uUEfxwmKJJxLZ_vee1qIUFnX5OMQ0zGSGZKdR80sf_BwLuBaUL7-OF_rLOSFH3PZs1w1Jr5hg-ZhemSi9r1ovPMwZjK5mGy-Dvl4zzMlXGf2zulOPXvnxC0kTIOejpD9nO7n9mXymjQop3GI1p5eXrW5a2SdiPu2CNtz_wX_G0d_WmcOOW_F5xEn-ZFwMJEEF9wTyhPJFSlQnISEl-mrptQLDR4EFGJfIxTN5GCEskVDdI0RQrHkQgsQC0bZGoJbCQsbihdvBvLMZ5woaQXHRCZBiolUUAs2Bk5nt0VEhvMlCaROS6NvmHaNwx9Y8G2AaZqx-9v9M600Gfd-Jh1usiHzq4idmzBxgg5hvGiF0F4pgbDnIWY4pESBxYsFoC-PROLPxzQIwu2CoSrK1qCu9n_V2eD-x4b3g4Z1pj-gQW7BtbPXprF1_UOJctfa74BP9rNFrs4jc9XYKrYQqg30axCDUFVazCey-G66eyv-d8BWQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pathogenesis+in+Menstrual+Cycle%E2%80%90Linked+CNS+Disorders&rft.jtitle=Annals+of+the+New+York+Academy+of+Sciences&rft.au=B%C3%84CKSTR%C3%96M%2C+TORBJ%C3%96RN&rft.au=ANDERSSON%2C+AGNETA&rft.au=ANDRE%C3%89%2C+LOTTA&rft.au=BIRZNIECE%2C+VITA&rft.date=2003-12-01&rft.pub=Blackwell+Publishing+Ltd&rft.issn=0077-8923&rft.eissn=1749-6632&rft.volume=1007&rft.issue=1&rft.spage=42&rft.epage=53&rft_id=info:doi/10.1196%2Fannals.1286.005&rft.externalDBID=10.1196%252Fannals.1286.005&rft.externalDocID=NYAS42 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0077-8923&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0077-8923&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0077-8923&client=summon |